Search clinical trials for: safety and efficacy study with ertugliflozin (PF-04971729, MK-8835)

Total 480007 results

Merck Sharp & Dohme LLC
Pfizer

Active, not recruiting

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Type 2 Diabetes Mellitus

United States, Belgium, Canada, Colombia, Costa Rica, Dominican Republic, France, Guatemala, Hungary, Israel, Italy, Malaysia, Mauritius, Mexico, Philippines, Poland, Russian Federation, Saudi Arabia, Turkey, Ukraine, United Arab... and more
Merck Sharp & Dohme LLC
Pfizer

Completed

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC
Pfizer

Completed

Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC
Pfizer

Completed

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Hypertension | Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC
Pfizer

Completed

Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

Type 2 Diabetes Mellitus | Hepatic Impairment
Merck Sharp & Dohme LLC
Pfizer

Completed

Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)

Healthy
Merck Sharp & Dohme LLC
Pfizer

Completed

A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)

Healthy Volunteer
Merck Sharp & Dohme LLC
Pfizer

Completed

A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)

Diabetes Mellitus, Type 2 | Adult
Merck Sharp & Dohme LLC
Pfizer

Completed

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)

Type 2 Diabetes Mellitus (T2DM)
Merck Sharp & Dohme LLC
Pfizer

Completed

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

Type 2 Diabetes Mellitus | Renal Impairment
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)

Type 2 Diabetes Mellitus
Olympus Biotech Corporation

Completed

The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study (TRANS-North)

Diabetic Foot Ulcer of Neuropathic Origin

Belgium, Germany, Poland, Croatia, Bulgaria, Denmark, Slovakia, Hungary, Netherlands, Sweden
Children's Hospital of Philadelphia
National Library of Medicine (NLM)

Completed

Comprehensive Clinical Decision Support (CDS) for the Primary Care of Premature Infants (PreemieCDS)

Prematurity

United States
Prince of Songkla University

Active, not recruiting

Gastric Volume After Ingestion of Carbohydrate Drink vs Water in Obese Volunteers

Obesity | Gastric Emptying

Thailand
Assiut University

Not yet recruiting

Intrapartum Ultrasonography in Evaluation of the Progress of Labor

Progress pf Labor
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russian Federation, Sweden, Turkey, United Kingdom
Helsinki University Central Hospital

Recruiting

Identifying Reasons for Non-adherence in Patients With Multi-morbidity

Chronic Disease | Medication Adherence | Medication Nonadherence

Finland
MTI University

Unknown

Triceps Taping on Elbow Flexion Tightness in Extended Erb's Palsy

Deformity Flexion

Egypt
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Type 2 Diabetes Mellitus
Pfizer

Withdrawn

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

United States
Lithuanian University of Health Sciences

Completed

Temporary Hydrostatic Splint Therapy and Its Effects on Occlusal Forces

Temporomandibular Joint Disorders

Lithuania
Pfizer
Merck Sharp & Dohme LLC

Completed

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

Advanced Solid Tumors

United States
Merck Sharp & Dohme LLC

Completed

A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

Urinary Bladder, Overactive
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Karen-Lise Garm Spindler
Zealand University Hospital; Vejle Hospital

Recruiting

OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer (OPTIMISE)

Colorectal Cancer | Metastatic Cancer

Denmark
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Terminated

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

Renal Impairment

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Completed

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

Neuroendocrine Tumors | Metastatic Neuroendocrine Tumors

United States
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Diabetes Mellitus, Type 2

Taiwan, United States, Hungary, Canada, Slovakia, India, Bulgaria
Merck Sharp & Dohme LLC

Terminated

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Non-small Cell Lung Cancer (NSCLC) | Triple Negative Breast Cancer (TNBC) | NUT Midline Carcinoma (NMC) | Castration-resistant Prostate Cancer (CRPC)
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Shire

Completed

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease (OPERA)

Crohn's Disease

Korea, Republic of, United States, Spain, Japan, Serbia, Germany, Belgium, Netherlands, Poland, Austria, Bulgaria, Canada, France, Norway, Slovakia, South Africa
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Pfizer

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B (BENEGENE-2)

Hemophilia B

Germany, United Kingdom, Canada, Australia, Taiwan, Japan, France, Turkey, Korea, Republic of, United States, Brazil, Greece, Saudi Arabia, Sweden
Quark Pharmaceuticals
Pfizer

Terminated

Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema (DEGAS)

Diabetes Complications | Diabetic Retinopathy

United States, United Kingdom, Italy, Israel, Germany, Peru, Denmark, India
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
National Taiwan University Hospital

Unknown

Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

Taiwan

3

Subscribe